{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:21:30Z","timestamp":1774437690937,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.2215\/cjn.04340510","type":"journal-article","created":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T01:12:24Z","timestamp":1283476344000},"page":"2220-2228","source":"Crossref","is-referenced-by-count":129,"title":["Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease"],"prefix":"10.2215","volume":"5","author":[{"given":"Christoph","family":"Wanner","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o P.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[]},{"given":"Gabor E.","family":"Linthorst","sequence":"additional","affiliation":[]},{"given":"Andreas L.","family":"Serra","sequence":"additional","affiliation":[]},{"given":"L\u00e1szl\u00f3","family":"Mar\u00f3di","sequence":"additional","affiliation":[]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Cianciaruso","sequence":"additional","affiliation":[]},{"given":"Bojan","family":"Vujkovac","sequence":"additional","affiliation":[]},{"given":"Roberta","family":"Lemay","sequence":"additional","affiliation":[]},{"given":"Dana","family":"Beitner-Johnson","sequence":"additional","affiliation":[]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R2-14-20230601","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R3-14-20230601","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R4-14-20230601","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"R5-14-20230601","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R6-14-20230601","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-14-20230601","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R8-14-20230601","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"R9-14-20230601","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R10-14-20230601","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R11-14-20230601","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: Sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R12-14-20230601","first-page":"7","article-title":"Fetal pathology in Fabry's disease and mucopolysaccharidosis type I","volume":"34","author":"Elleder","year":"1998","journal-title":"Cesk Patol"},{"key":"R13-14-20230601","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"R14-14-20230601","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R15-14-20230601","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore"},{"key":"R16-14-20230601","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R17-14-20230601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R18-14-20230601","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","article-title":"Longitudinal studies on the rate of decline in renal function with age","volume":"33","author":"Lindeman","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"R19-14-20230601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2003.09.026","article-title":"Measured and estimated GFR in healthy potential kidney donors","volume":"43","author":"Rule","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R20-14-20230601","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2013measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"R21-14-20230601","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"R22-14-20230601","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in Fabry patients who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R23-14-20230601","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/ndt\/gfp105","article-title":"Nephropathy in Fabry disease: The importance of early diagnosis and testing in high-risk populations","volume":"24","author":"Oqvist","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R24-14-20230601","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"R25-14-20230601","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2215\/CJN.06900909","article-title":"Enzyme replacement therapy and Fabry nephropathy","volume":"5","author":"Warnock","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-14-20230601","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ki.2008.200","article-title":"Gender differences in predictors of the decline of renal function in the general population","volume":"74","author":"Halbesma","year":"2008","journal-title":"Kidney Int"},{"key":"R27-14-20230601","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R28-14-20230601","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"R29-14-20230601","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"R30-14-20230601","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias","volume":"335","author":"MacMahon","year":"1990","journal-title":"Lancet"},{"key":"R31-14-20230601","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: Natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01277230-201012000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T20:33:14Z","timestamp":1685651594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01277230-201012000-00014"}},"subtitle":["Natural History Data from the Fabry Registry"],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04340510","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}